COMMUNIQUÉS West-GlobeNewswire

-
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
17/04/2024 -
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
17/04/2024 -
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
17/04/2024 -
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
17/04/2024 -
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
17/04/2024 -
Zylö announces the creation and spinout of Atticus Pharma Inc.
17/04/2024 -
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
17/04/2024 -
Ocean Drive Plastic Surgery Founder Dr. Alan Durkin Appointed VIO Med Spa Chief Medical Officer
17/04/2024 -
Repligen to Report First Quarter 2024 Financial Results
17/04/2024 -
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17/04/2024 -
Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale
17/04/2024 -
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
17/04/2024 -
Treace to Present at Bank of America Health Care Conference
17/04/2024 -
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
17/04/2024 -
Tilray Brands Lights Up 420 With Music Festivals and Celebrations Across The Country
17/04/2024 -
Medigene to Present at Upcoming Scientific Conferences
17/04/2024 -
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
17/04/2024 -
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
17/04/2024 -
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17/04/2024
Pages